- Radboud University Medical Center
ImaginAb exist to challenge, create and to transform. We align this vision through every aspect of our strategy from development to market authorization and feedback.
Everything we do is focused on reimagining a new world of healthcare potential, optimising the immuno oncology patient care path and delivering greater insight to physicians and comfort to patients.
Our development process is precise and prompt. We partner with global pharmaceutical leaders and world-class clinicians to develop, trial and bring our innovative products to market.
Our approach is targeted and precise. In the diagram below, we show the steps ImaginAb takes to generate an imaging minibody or cys diabody. ImaginAb has developed the ability to rapidly discover and screen new imaging agents. From concept to clinical study, we’re able to complete everything in approximately 18 months following our 3 stage path.
In just 4-6 months, we’re able to achieve from ideal to lead binder.
The binder progresses to lead product. We then add a reporter tag to allow visualization, and validate the product in pre-clinical models.
Safety studies are carried out alongside a clinical grade manufacture, to enable us to undertake a clinical study. This takes approximately 1 year.